^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
Published date:
10/29/2021
Excerpt:
In the PROMIX trial, women with localized HER2- BC received neoadjuvant epirubicin/docetaxel...In Kaplan–Meier estimates of ER+ patients divided by the median of the post/pre-treatment sTK1 ratio at the first treatment cycle, OS was 97.7% and 78% (p = 0.005), and DFS was 90.7% and 68% (p = 0.006), respectively.
DOI:
https://doi.org/10.3390/cancers13215442
Trial ID:
